• Explore /
  • Poster
  • / Patient-reported outcomes (PROs) from KATHERINE: A phase III study of adjuvant trastuzumab emtansine (T-DM1) versus trastuzumab (H) in patients (pts) with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer.

Patient-reported outcomes (PROs) from KATHERINE: A phase III study of adjuvant trastuzumab emtansine (T-DM1) versus trastuzumab (H) in patients (pts) with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer.

Abstract Poster

Authors

null

Andreas Schneeweiss

National Center for Tumor Diseases, Heidelberg University Hospital and German Cancer Research Center, Heidelberg, Germany

Andreas Schneeweiss , Sibylle Loibl , Eleftherios P. Mamounas , Gunter von Minckwitz , Max S. Mano , Michael Untch , Chiun-Sheng Huang , Priya Rastogi , Pier Franco Conte , Veronique D'hondt , Andres Redondo , Ljiljana Stamatovic , Herve R. Bonnefoi , Hugo Raul Castro Salguero , Hans Holger Fischer , Tanya A. Wahl , Chunyan Song , Steven Blotner , Peter Trask , Charles E. Geyer Jr.

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2019 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Breast Cancer—Local/Regional/Adjuvant

Track

Breast Cancer

Sub Track

Adjuvant Therapy

Clinical Trial Registration Number

NCT01772472

Citation

J Clin Oncol 37, 2019 (suppl; abstr 513)

DOI

10.1200/JCO.2019.37.15_suppl.513

Abstract #

513

Poster Bd #

5

Abstract Disclosures

Similar Posters

First Author: Santiago Escrivá

First Author: Hope S. Rugo

First Author: Erika Paige Hamilton

First Author: Erika Paige Hamilton